Trastuzumab and other HER2-targeted drugs can weaken the heart's pumping, so your team scans your heart before and during treatment. If the pumping measure (ejection fraction) falls past a set line, the drug is usually paused, the scan repeated in 3 to 4 weeks, and treatment restarted if it recovers. The lines differ by drug and country. Report new breathlessness or ankle swelling straight away.
Each HER2-targeted product's label sets its own rule for a fall in left ventricular ejection fraction (LVEF), and the rules differ between products and, for trastuzumab and lapatinib, between the US and EU texts. Trastuzumab, US label: LVEF before treatment, every 3 months during and at the end, and every 6 months for at least 2 years after adjuvant treatment; withhold for at least 4 weeks for an absolute fall of 16 points or more, or an LVEF below the institution's normal limit with a fall of 10 points or more; it may be resumed if within 4 to 8 weeks LVEF is back within normal limits and no more than 15 points below baseline; permanently discontinue for a fall lasting more than 8 weeks or more than 3 suspensions. Trastuzumab, EU SmPC: suspend for a fall of 10 points or more to below 50 per cent, repeat LVEF within about 3 weeks, and strongly consider discontinuation if it has not improved or symptomatic heart failure has developed, unless the benefit outweighs the risk; refer to a cardiologist. Pertuzumab with trastuzumab (US and EU, and the fixed-dose subcutaneous combination): withhold for at least 3 weeks in metastatic disease for LVEF below 40 per cent, or 40 to 45 per cent with a fall of 10 points or more; in early breast cancer for LVEF below 50 per cent with a fall of 10 points or more. Trastuzumab emtansine (US and EU): in metastatic disease withhold for LVEF below 40 per cent, or 40 to 45 per cent with a fall of 10 points or more; in early breast cancer for LVEF below 45 per cent, or 45 to 49 per cent with a fall of 10 points or more; repeat within about 3 weeks. Trastuzumab deruxtecan (US and EU): interrupt for LVEF 40 to 45 per cent with a fall of 10 to 20 points, for LVEF below 40 per cent or for a fall of more than 20 points; repeat within 3 weeks; permanently discontinue if the lower line is confirmed or for symptomatic heart failure. Zanidatamab (US and EU) and margetuximab (US) follow the 16-point and 10-point pattern of US trastuzumab, with 50 per cent as the limit (for margetuximab, where the institution has no normal limit of its own). Lapatinib: discontinue for a Grade 2 or greater LVEF decrease (US) or grade 3 or greater symptoms (EU), or LVEF below the lower limit of normal; it may be restarted at a reduced dose after at least 2 weeks if LVEF is normal and there are no symptoms.
The 2022 ESC guideline grades by severity instead. It recommends temporary interruption for moderate or severe symptomatic dysfunction (Class I, Level C, with heart failure therapy at Class I, Level B) and temporary interruption with heart failure therapy for a new asymptomatic LVEF below 40 per cent (Class I, Level C); says continuation should be considered with a new asymptomatic LVEF of 40 to 49 per cent with more frequent monitoring (Class IIa, Level B), with an ACE inhibitor or ARB and a beta-blocker (Class I, Level C); and says, in a footnote with no grade of its own, that resumption should be considered once LVEF is 40 per cent or more and symptoms have gone. ESMO (2020) is close to ESC. So a person with an asymptomatic LVEF in the 40s can fall on the hold side of a label and on the consider-continuing side of the guideline. Two small single-arm studies continued treatment on heart medicines: SAFE-HEaRt (31 patients with an LVEF of 40 to 49 per cent, supported by Genentech) and SCHOLAR (20 patients with an LVEF between 40 per cent and the lower limit of normal, or a fall of 15 points or more); in each, 1 in 10 had a cardiac event or a further marked fall. This page explains care; the treating team's own protocol comes first.
Why: This is the schedule the US label recommends. The EU SmPC asks for the same 3-monthly checks and for checks every 6 months until 24 months after the last dose; for people who also had an anthracycline it recommends yearly checks up to 5 years from the last dose, or longer if LVEF keeps falling. The EU text says monitoring may help to identify patients who develop cardiac dysfunction.
“Conduct thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan. The following schedule is recommended:”
Genentech, on DailyMed (US National Library of Medicine) 2026
Why: The trastuzumab emtansine labels give every three months as an example. The pertuzumab labels say about every 12 weeks, and once during treatment given before surgery. The margetuximab US label says every 3 months during treatment and at its end. The trastuzumab deruxtecan labels say at regular intervals as clinically indicated, and the zanidatamab labels say at regular intervals with no number. The lapatinib labels ask for LVEF before treatment and continued evaluation during it with no interval; its trials checked about every 8 weeks. ESC (2022) recommends an echocardiogram every 3 months on neoadjuvant or adjuvant HER2-targeted therapy (Class I, Level B).
“Assess LVEF prior to initiation of KADCYLA and at regular intervals (e.g. every three months) during treatment to ensure the LVEF is within the institution's normal limits.”
Genentech, on DailyMed (US National Library of Medicine) 2026
Why: The US label gives the numbers without a stated reason. It asks for LVEF to be repeated at 4-week intervals while the drug is withheld, and says the safety of continuing or resuming trastuzumab in people whose heart function it has reduced has not been studied. The US label for trastuzumab given under the skin with hyaluronidase carries the same rule.
“Withhold Herceptin for ≥ 16% absolute decrease in LVEF from pre-treatment values or an LVEF value below institutional limits of normal and ≥ 10% absolute decrease in LVEF from pretreatment values”
Genentech, on DailyMed (US National Library of Medicine) 2026
Why: The label gives these limits without a stated reason. Its boxed warning adds: discontinue trastuzumab in people having adjuvant treatment, and withhold it in people with metastatic disease, for a clinically significant decrease in left ventricular function.
“Herceptin may be resumed if, within 4–8 weeks, the LVEF returns to normal limits and the absolute decrease from baseline is ≤ 15%.”
Genentech, on DailyMed (US National Library of Medicine) 2026
Why: The EU rule differs from the US one: it has no 16-point criterion, uses 50 per cent where the US label uses the institution's normal limit, and asks for the repeat scan at about 3 weeks where the US label says 4. The SmPC notes that the safety of continuing or resuming trastuzumab in people who develop cardiac dysfunction has not been prospectively studied.
“If left ventricular ejection fraction (LVEF) percentage drops ≥ 10 points from baseline AND to below 50 %, treatment should be suspended and a repeat LVEF assessment performed within approximately 3 weeks.”
Why: Unlike the US label, the EU text sets no number of weeks or of holds after which trastuzumab is stopped. It says symptomatic heart failure should be treated with standard heart failure medicines, and that most patients who developed heart failure or asymptomatic dysfunction in the pivotal trials improved on an ACE inhibitor or ARB and a beta-blocker. It also says patients who develop asymptomatic cardiac dysfunction may benefit from more frequent monitoring, for example every 6 to 8 weeks.
“If LVEF has not improved, or has declined further, or if symptomatic congestive heart failure (CHF) has developed, discontinuation of Herceptin should be strongly considered, unless the benefits for the individual patient are deemed to outweigh the risks. All such patients should be referred for assessment by a cardiologist and followed up.”
Why: The US and EU pertuzumab texts give the same numbers. Treatment may be resumed in metastatic disease once LVEF is above 45 per cent, or is 40 to 45 per cent and less than 10 points below the pre-treatment value; in early breast cancer once it is 50 per cent or more, or less than 10 points below the pre-treatment value. The fixed-dose injection of pertuzumab and trastuzumab under the skin (Phesgo) carries the same thresholds in both regions. These numbers are not those of the trastuzumab labels, although the two drugs are given together.
“Perjeta and trastuzumab may be resumed if the LVEF has recovered to > 45%, or to 40-45% associated with a difference of < 10% points below pre-treatment values.”
Why: Three texts for the same medicines use three strengths. US Perjeta: consider permanent discontinuation. EU Perjeta and EU Phesgo: discontinuation should be strongly considered unless the benefits for the individual patient are deemed to outweigh the risks. US Phesgo: permanently discontinue if, after a repeat assessment within approximately 3 weeks, LVEF has not improved, has declined further, or the patient is symptomatic. The boxed warning of the US Perjeta label is firmer than its body text: discontinue pertuzumab for a confirmed clinically significant decrease in left ventricular function. The labels do not explain the difference.
“If the LVEF declines and has not improved, or has declined further at the subsequent assessment, consider permanent discontinuation of PERJETA and trastuzumab”
Genentech, on DailyMed (US National Library of Medicine) 2026
Why: The US and EU texts carry the same tables. With a smaller fall (less than 10 points) in the same band, treatment continues and the scan is repeated within 3 weeks. Both say to discontinue for symptomatic heart failure; in early breast cancer that row also covers Grade 3 to 4 left ventricular systolic dysfunction or heart failure, and Grade 2 heart failure with LVEF below 45 per cent. The US label reports, from a retrospective observational study, that 22 per cent (7 of 32) of people with metastatic breast cancer who started with an LVEF of 40 to 49 per cent developed heart failure or a fall in LVEF of more than 10 per cent.
“For patients with MBC, if, at routine monitoring, LVEF is < 40%, or is 40% to 45% with a 10% or greater absolute decrease below the pretreatment value, withhold KADCYLA and repeat LVEF assessment within approximately 3 weeks. Permanently discontinue KADCYLA if the LVEF has not improved or has declined further.”
Genentech, on DailyMed (US National Library of Medicine) 2026
Why: The US and EU tables are the same. With LVEF above 45 per cent and a fall of 10 to 20 points, or LVEF of 40 to 45 per cent and a fall of less than 10 points, treatment continues, with a repeat scan within 3 weeks in the second case. After an interruption for LVEF of 40 to 45 per cent with a fall of 10 to 20 points, treatment resumes at the same dose if LVEF recovers to within 10 per cent from baseline, in the label's words, and is stopped for good if it does not. Unlike the trastuzumab labels, neither text sets a scan interval: both say at regular intervals as clinically indicated.
“Permanently discontinue ENHERTU if LVEF of less than 40% or absolute decrease from baseline of greater than 20% is confirmed. Permanently discontinue ENHERTU in patients with symptomatic congestive heart failure (CHF)”
Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026
Why: The US and EU tables match on these numbers. The US table has a row the EU table does not: stop for good for confirmed symptomatic congestive heart failure. The EU SmPC says that if LVEF declines and has not improved, or has declined further at the next assessment, zanidatamab should be discontinued as its table recommends. The US label says the safety of zanidatamab has not been established in people whose baseline ejection fraction is below 50 per cent.
“Resume ZIIHERA treatment within 4 to 8 weeks if LVEF returns to normal limits and the absolute decrease is ≤ 15% points from baseline.”
Jazz Pharmaceuticals, on DailyMed (US National Library of Medicine) 2026
Why: The US label asks for a baseline LVEF within 4 weeks before the first dose, LVEF every 3 months during treatment and at its end, and a repeat at 4-week intervals while the drug is withheld. It gives no reason for the numbers, and says margetuximab has not been studied in people with a pre-treatment LVEF below 50 per cent. No EU product information for margetuximab was found.
“MARGENZA dosing may be resumed if, within 8 weeks, LVEF returns to normal limits and absolute decrease from baseline is ≤ 15%.”
TerSera Therapeutics, on DailyMed (US National Library of Medicine) 2025
Why: The two texts differ on the grade: the US label names a decreased LVEF that is Grade 2 or greater on NCI CTCAE version 3.0, the EU SmPC symptoms associated with decreased LVEF that are grade 3 or greater. The reduced restart doses are 1,000 mg a day with capecitabine and 1,250 mg a day with letrozole (US) or an aromatase inhibitor (EU); the EU text adds 750 mg a day with trastuzumab. The US label says most LVEF decreases in trials (greater than 57 per cent) occurred within the first 12 weeks of treatment.
“TYKERB should be discontinued in patients with a decreased left ventricular ejection fraction (LVEF) that is Grade 2 or greater by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v3.0), and in patients with an LVEF that drops below the institution’s lower limit of normal (LLN)”
Novartis, on DailyMed (US National Library of Medicine) 2024
Why: ESC grades the problem by severity instead of by a fall from baseline alone: severe dysfunction without symptoms is a new LVEF below 40 per cent. For moderate or severe symptomatic dysfunction it recommends the same temporary interruption, with the decision to restart made by a multidisciplinary team after left ventricular function has improved and symptoms have resolved (Class I, Level C), and heart failure therapy (Class I, Level B). For mild symptoms it recommends heart failure therapy and a multidisciplinary decision on continuing or interrupting (Class I, Level C). ESMO (2020) says trastuzumab or any HER2-based therapy should be withheld until cardiac status has stabilised in a patient with signs and symptoms of heart failure, or without symptoms and an LVEF below 40 per cent [I, A].
“Temporary interruption of HER2-targeted therapy and initiation of HF therapy is recommended in patients who develop asymptomatic severe CTRCD.”
ESC, European Heart Journal; read from the publisher's PDF in an open university repository 2022 · Class I, Level C
Why: ESC recommends the ACE inhibitor or ARB and beta-blocker in this group (Class I, Level C). Its text is firmer than its table: the text says treatment should be continued, the table that continuation should be considered. This is where guideline and labels part. The EU trastuzumab SmPC suspends treatment for a fall of 10 points or more to below 50 per cent; the pertuzumab labels withhold in early breast cancer for the same fall; the trastuzumab emtansine labels withhold in early breast cancer below 45 per cent, or at 45 to 49 per cent with a fall of 10 points or more. ESMO (2020) says it is possible that trastuzumab may be continued with mild asymptomatic reductions in LVEF [III, A]. With LVEF still 50 per cent or more and only a significant fall in strain or a rise in troponin or natriuretic peptide, ESC recommends continuing with more frequent monitoring (Class I, Level C).
“Continuation of HER2-targeted therapy should be considered in patients who develop asymptomatic moderate (LVEF 40–49%) CTRCD”
ESC, European Heart Journal; read from the publisher's PDF in an open university repository 2022 · Class IIa, Level B
Why: This is a footnote to ESC's Class I, Level C recommendations and carries no grade of its own; the text adds that recovery to 50 per cent or more is ideal. It is looser than the labels: US trastuzumab asks for LVEF back within normal limits and no more than 15 points below baseline within 4 to 8 weeks, and pertuzumab in early breast cancer for 50 per cent or more, or less than 10 points below baseline. ESMO (2020) says resumption should be considered when LVEF is 40 per cent or more and/or heart failure symptoms have resolved, supported by continued heart failure treatment and periodic biomarker and LVEF checks [III, B]. Where symptoms do not resolve or LVEF stays below 40 per cent, both say resumption may be considered if no alternative treatment exists (ESMO [IV, C]; ESC in a figure footnote).
“For patients where HER2-targeted therapy has been interrupted and who have recovered LVEF ≥ 40% and are now asymptomatic, resumption of HER2-targeted therapy should be considered”
ESC, European Heart Journal; read from the publisher's PDF in an open university repository 2022
Why: The US trastuzumab label asks prescribers to give this advice, with weight gain of more than 5 pounds in 24 hours as its figure. The US patient guides for trastuzumab deruxtecan and zanidatamab and the EU leaflets for trastuzumab, pertuzumab and trastuzumab emtansine give similar lists and ask patients to tell their doctor or nurse right away, straight away or immediately. ESMO says early recognition of the signs and symptoms of heart failure is vital to allow early treatment.
“Advise patients to contact a health care professional immediately for any of the following: new onset or worsening shortness of breath, cough, swelling of the ankles/legs, swelling of the face, palpitations, weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness”
Genentech, on DailyMed (US National Library of Medicine) 2026
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
There are two kinds of rule and they do not agree. The dose rule for each product is its own label, and a label is the right source for a hold, restart or stop rule. The labels differ from each other: US trastuzumab, zanidatamab and US margetuximab act on a fall of 16 points, or 10 points to below a normal limit, hold for at least 4 weeks and allow up to 8 weeks for recovery; EU trastuzumab acts on a fall of 10 points or more to below 50 per cent and repeats the scan at about 3 weeks; pertuzumab and trastuzumab emtansine use fixed bands with a hold or repeat scan at about 3 weeks (in metastatic disease, both: below 40 per cent, or 40 to 45 per cent with a fall of 10 points or more; in early breast cancer, pertuzumab: below 50 per cent with a fall of 10 points or more; trastuzumab emtansine: below 45 per cent, or 45 to 49 per cent with a fall of 10 points or more); trastuzumab deruxtecan interrupts only at 40 to 45 per cent with a fall of 10 to 20 points, below 40 per cent or after a fall of more than 20 points; lapatinib uses a CTCAE grade, and the US and EU texts name different grades. The management guideline is the 2022 ESC cardio-oncology guideline, the most recent graded text (no later edition or focused update was found on 18 November 2026): it grades by severity, recommends temporary interruption for symptomatic moderate or severe dysfunction or a new asymptomatic LVEF below 40 per cent (Class I, Level C), leaves the choice between continuing and interrupting in mild symptomatic dysfunction to a multidisciplinary decision (Class I, Level C), and says continuation should be considered at 40 to 49 per cent without symptoms (Class IIa, Level B) with an ACE inhibitor or ARB and a beta-blocker (Class I, Level C). ESMO (2020) takes a similar line with its own grades: withhold with heart failure or LVEF below 40 per cent [I, A]; trastuzumab may possibly be continued with mild asymptomatic reductions [III, A]. ESC grades its continue-at-40-to-49 advice Level B and ESMO grades its own Level III (prospective cohort studies). The prospective studies read for this page are two single-arm studies of 31 and 20 patients; SCHOLAR's authors wrote in 2019 that it was one of only two trials to have tested continuing trastuzumab despite cardiotoxicity prospectively. No randomised comparison of continuing against holding was found in the sources read. Both positions are shown here; which applies to a given person is for the treating team and, as ESC recommends, a multidisciplinary discussion.
Genentech, on DailyMed (US National Library of Medicine) 2026 · Roche, on the European Medicines Agency website 2025 · Genentech, on DailyMed (US National Library of Medicine) 2026 · Roche, on the European Medicines Agency website 2026 · Genentech, on DailyMed (US National Library of Medicine) 2026 · Daiichi Sankyo, on DailyMed (US National Library of Medicine) 2026 · Jazz Pharmaceuticals, on DailyMed (US National Library of Medicine) 2026 · TerSera Therapeutics, on DailyMed (US National Library of Medicine) 2025 · Novartis, on DailyMed (US National Library of Medicine) 2024 · ESC, European Heart Journal; read from the publisher's PDF in an open university repository 2022 · ESMO, Annals of Oncology (no external funding; production costs covered by ESMO) 2020 · Lynce et al., Breast Cancer Research and Treatment 2019 · Leong et al., JACC: CardioOncology (supported by Hamilton Health Sciences) 2019
Where it differs: US: withhold for at least 4 weeks for a fall of 16 points or more, or an LVEF below the institution's normal limit with a fall of 10 points or more; repeat LVEF every 4 weeks; resume if recovered within 4 to 8 weeks; permanently discontinue for a fall lasting more than 8 weeks or more than 3 suspensions. EU: suspend for a fall of 10 points or more to below 50 per cent; repeat within about 3 weeks; strongly consider discontinuation if not improved or symptomatic, unless benefit outweighs risk; cardiologist referral. Follow-up after adjuvant treatment: US every 6 months for at least 2 years; EU every 6 months until 24 months, then yearly up to 5 years after an anthracycline.
Evidence: Regulatory texts for the same medicine from the same company; neither states the evidence for its thresholds. Both say the safety of continuing or resuming trastuzumab after cardiac dysfunction has not been studied (EU: not prospectively studied).
Genentech, on DailyMed (US National Library of Medicine) 2026 · Roche, on the European Medicines Agency website 2025
Where it differs: Same LVEF thresholds and 3-week hold as intravenous pertuzumab in both regions. The US label is firmer on stopping than US Perjeta: permanently discontinue if, after a repeat assessment within approximately 3 weeks, LVEF has not improved, has declined further, or the patient is symptomatic. It also asks for LVEF every 6 months for at least 2 years after adjuvant treatment. The EU SmPC says discontinuation should be strongly considered unless benefits outweigh risks.
Evidence: Regulatory labels. The US label reports from the FeDeriCa trial heart failure (NYHA class III or IV) with an LVEF fall of 10 points or more to below 50 per cent in 0.8 per cent of the Phesgo arm.
Genentech, on DailyMed (US National Library of Medicine) 2026 · Roche, on the European Medicines Agency website 2026
Where it differs: Patients with stage I to IV HER2-positive breast cancer and an LVEF of 40 to 49 per cent without heart failure symptoms were given trastuzumab, trastuzumab with pertuzumab, or trastuzumab emtansine without interruption, with a beta-blocker and an ACE inhibitor or ARB unless contraindicated, cardiology visits and serial echocardiograms.
Evidence: A single-arm pilot at three US centres: 31 enrolled, 30 evaluable; 27 (90 per cent) completed planned treatment; 2 had a cardiac event and 1 an asymptomatic fall in LVEF to 35 per cent or less. At a median follow-up of 42 months, mean LVEF in the 23 patients with data was 52.1 per cent against 44.9 per cent at baseline; one more patient had developed symptomatic heart failure, and there were no cardiac deaths. The authors name the small sample, the lack of randomisation and the mixed population as limits. Supported by Genentech (Roche), which supplied the study drugs, with NCI and foundation grants.
Lynce et al., Breast Cancer Research and Treatment 2019 · Khoury et al., Breast Cancer Research and Treatment 2021
Where it differs: Patients on adjuvant trastuzumab for stage I to III breast cancer with an LVEF between 40 per cent and the lower limit of normal, or a fall of 15 points or more from baseline, continued trastuzumab with an ACE inhibitor and/or beta-blocker in a cardio-oncology clinic, with serial echocardiograms for 1 year.
Evidence: A phase I single-arm trial at one Canadian centre: 20 participants; 18 (90 per cent) received all planned doses; 2 (10 per cent) developed heart failure with LVEF below 40 per cent, which improved to nearly normal after trastuzumab was permanently stopped; no deaths. The authors conclude that about 10 per cent of patients may develop moderate to severe heart failure with this approach, and name the 1-year follow-up, single centre and small sample as limits. Supported by Hamilton Health Sciences; one author reports advisory-board honoraria from Roche.
Leong et al., JACC: CardioOncology (supported by Hamilton Health Sciences) 2019
Where it differs: For an asymptomatic fall of 10 per cent or more from baseline, or a drop to 40 to below 50 per cent, on trastuzumab: cardiology consultation, consider cardioprotective treatment, consider monthly biomarkers, and if trastuzumab is stopped repeat LVEF within 3 to 6 weeks and resume if LVEF has normalised to above 50 per cent. With heart failure or LVEF below 40 per cent: withhold until cardiac status has stabilised and discuss risks and benefits of continuing with the multidisciplinary team and the patient.
Evidence: ESMO grades these [III, A] and [I, A]. Its 3 to 6 week repeat and its restart line of above 50 per cent are not the same as ESC's (restart should be considered from 40 per cent). No external funding; several authors declare advisory roles with manufacturers of HER2-targeted drugs.
ESMO, Annals of Oncology (no external funding; production costs covered by ESMO) 2020
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Trastuzumab, US: when to stop for good “Permanently discontinue Herceptin for a persistent (> 8 weeks) LVEF decline or for suspension of Herceptin dosing on more than 3 occasions for cardiomyopathy.” | Not graded (regulatory label) | Genentech, on DailyMed (US National Library of Medicine) 2026 |
| Trastuzumab, US: scans while the drug is withheld “Repeat LVEF measurement at 4 week intervals if Herceptin is withheld for significant left ventricular cardiac dysfunction” | Not graded (regulatory label) | Genentech, on DailyMed (US National Library of Medicine) 2026 |
| Trastuzumab, EU: scan schedule during and after treatment “Cardiac assessments, as performed at baseline, should be repeated every 3 months during treatment and every 6 months following discontinuation of treatment until 24 months from the last administration of Herceptin.” | Not graded (regulatory label) | Roche, on the European Medicines Agency website 2025 |
| Pertuzumab, EU: restart in early breast cancer “Perjeta and trastuzumab may be resumed if the LVEF has recovered to ≥50% or to a difference of < 10% points below pre-treatment values.” | Not graded (regulatory label) | Roche, on the European Medicines Agency website 2026 |
| Pertuzumab, EU: when LVEF has not recovered “If the LVEF has declined as indicated in section 4.2 and has not improved, or has declined further at the subsequent assessment, discontinuation of Perjeta and trastuzumab should be strongly considered, unless the benefits for the individual patient are deemed to outweigh the risks.” | Not graded (regulatory label) | Roche, on the European Medicines Agency website 2026 |
| Fixed-dose combination, US: when LVEF has not recovered “If after a repeat assessment within approximately 3 weeks, the LVEF has not improved, has declined further, and/or the patient is symptomatic, permanently discontinue PHESGO” | Not graded (regulatory label) | Genentech, on DailyMed (US National Library of Medicine) 2026 |
| Fixed-dose combination, EU: hold in early breast cancer “Phesgo should be withheld for at least 3 weeks for a drop in LVEF to less than 50 % associated with a fall of ≥ 10 % points below pre-treatment values.” | Not graded (regulatory label) | Roche, on the European Medicines Agency website 2026 |
| Trastuzumab emtansine, US: early breast cancer “For patients with EBC, if, at routine monitoring, LVEF is < 45%, or is 45% to 49% with a 10% or greater absolute decrease below the pretreatment value, withhold KADCYLA and repeat LVEF assessment within approximately 3 weeks. Permanently discontinue KADCYLA if the LVEF has not improved or has declined further” | Not graded (regulatory label) | Genentech, on DailyMed (US National Library of Medicine) 2026 |
| Trastuzumab emtansine, EU: scans “Standard cardiac function testing (echocardiogram or multigated acquisition (MUGA) scanning) should be performed prior to initiation of treatment and also at regular intervals (e.g. every three months) during treatment.” | Not graded (regulatory label) | Roche, on the European Medicines Agency website 2026 |
| Trastuzumab deruxtecan, EU: when to stop for good “Enhertu should be permanently discontinued if LVEF of less than 40% or absolute decrease from baseline of greater than 20% is confirmed.” | Not graded (regulatory label) | Daiichi Sankyo, on the European Medicines Agency website 2026 |
| Zanidatamab, EU: when LVEF has not recovered “If the LVEF declines and has not improved, or has declined further at the subsequent assessment, Ziihera should be discontinued as recommended in Table 1 (see section 4.2).” | Not graded (regulatory label) | Jazz Pharmaceuticals, on the European Medicines Agency website 2026 |
| Margetuximab, US: when to stop for good “Permanently discontinue MARGENZA if LVEF decline persists for greater than 8 weeks, or if dosing is interrupted on greater than 3 occasions for LVEF decline.” | Not graded (regulatory label) | TerSera Therapeutics, on DailyMed (US National Library of Medicine) 2025 |
| Lapatinib, EU: when to discontinue “Tyverb should be discontinued in patients with symptoms associated with decreased left ventricular ejection fraction (LVEF) that are National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade 3 or greater or if their LVEF drops below the institutions lower limit of normal (see section 4.4).” | Not graded (regulatory label) | Novartis, on the European Medicines Agency website 2025 |
| ESC: moderate or severe symptomatic dysfunction “Temporary interruption of HER2-targeted treatment is recommended in patients who develop moderate or severe symptomatic CTRCD and the decision to restart should be based on a multidisciplinary approach after improvement of LV function and symptoms resolved.” | Class I, Level C | ESC, European Heart Journal; read from the publisher's PDF in an open university repository 2022 |
| ESC: mild symptomatic dysfunction “In patients who develop mild symptomatic CTRCD, HF therapy and a multidisciplinary approach regarding the decision to continue vs. interrupt HER2-targeted therapy are recommended.” | Class I, Level C | ESC, European Heart Journal; read from the publisher's PDF in an open university repository 2022 |
| ESC: restarting after severe asymptomatic dysfunction “A multidisciplinary approach regarding the decision to restart HER2-targeted treatment is recommended in patients with severe asymptomatic CTRCD.” | Class I, Level C | ESC, European Heart Journal; read from the publisher's PDF in an open university repository 2022 |
| ESC, in its text: asymptomatic LVEF of 40 to 49 per cent “In patients with asymptomatic moderate CTRCD (LVEF 40–49%), HER2-targeted treatment should be continued, and cardioprotective therapy (ACE-I/ARB and betablockers) is recommended with frequent cardiac monitoring.” | Guideline text; the matching table rows are Class IIa, Level B (continuation) and Class I, Level C (ACE inhibitor or ARB and beta-blocker) | ESC, European Heart Journal; read from the publisher's PDF in an open university repository 2022 |
| ESMO: heart failure, or LVEF below 40 per cent without symptoms “In addition, trastuzumab (or any HER2-based therapy) should be withheld until the cardiac status has stabilised. A discussion regarding the risks and benefits of continuation should be held with the multidisciplinary team and the patient [I, A].” | [I, A] | ESMO, Annals of Oncology (no external funding; production costs covered by ESMO) 2020 |
| ESMO: mild asymptomatic reductions (the grade is printed once, at the end of Recommendation 5.2, after this sentence) “It is possible that trastuzumab therapy may be continued with mild asymptomatic reductions in LVEF [III, A].” | [III, A] | ESMO, Annals of Oncology (no external funding; production costs covered by ESMO) 2020 |
| ESMO: restarting after an interruption “For a patient in whom trastuzumab therapy (or any HER2-targeted molecular therapy) has been interrupted, whose LVEF is ≥40% and/or whose signs and symptoms of HF have resolved, resumption of trastuzumab therapy should be considered, supported by:” | [III, B] | ESMO, Annals of Oncology (no external funding; production costs covered by ESMO) 2020 |
| ESMO: restarting when the heart has not recovered “For a patient in whom trastuzumab therapy (or any HER2-targeted molecular therapy) has been interrupted, whose signs and symptoms of HF do not resolve and/or LVEF remains <40%, resumption of trastuzumab therapy may be considered if no alternative therapeutic option exists.” | [IV, C] | ESMO, Annals of Oncology (no external funding; production costs covered by ESMO) 2020 |
Shares 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS), Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment, Cardiotoxicity (LVEF decline, cardiomyopathy), Cardio-oncology and the tags protocol, cardio-oncology.
Shares 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS), Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment, Cardiotoxicity (LVEF decline, cardiomyopathy), Cardio-oncology and the tags protocol, cardio-oncology.
Shares 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS), Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment, Cardiotoxicity (LVEF decline, cardiomyopathy), Cardio-oncology and the tags protocol, cardio-oncology.
Shares Margetuximab, Zanidatamab, Trastuzumab emtansine, Pertuzumab and the tag her2.
Shares Trastuzumab emtansine, Pertuzumab, Trastuzumab deruxtecan, Trastuzumab and the tag her2.
Shares Immune-related myocarditis from checkpoint inhibitors, European Society for Medical Oncology (ESMO) and the tag protocol.
Shares Cardio-oncology, Trastuzumab and the tag her2.
Shares Immune-related myocarditis from checkpoint inhibitors, European Society for Medical Oncology (ESMO) and the tag protocol.